In vivo selection of genetically modified erythroid cells using a Jak2-based cell growth switch

Molecular Therapy

Volumn 10, Issue 3, 2004, Pages 456-468

  Zhao, Shengming ^a   Weinreich, Michael A ^a   Ihara, Kenji ^a   Richard, Robert E ^a   Blau, C Anthony ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 20187; CHEMICAL INDUCER OF DIMERIZATION; CYTOKINE RECEPTOR; DNA; DRUG; FLT3 LIGAND; JANUS KINASE 2; MESSENGER RNA; MPL PROTEIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BETA THALASSEMIA; CELL FATE; CELL GROWTH; CELL LINEAGE; CELL SELECTION; CELL TRANSPLANTATION; CLINICAL MEDICINE; CONTROLLED STUDY; DNA MODIFICATION; DRUG RESPONSE; ENZYME ACTIVATION; ERYTHROID CELL; FEMALE; GENE THERAPY; GENETIC ENGINEERING; GRANULOCYTE; HEMATOPOIETIC CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DOMAIN; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOCYTE;

ANIMALS; B-LYMPHOCYTES; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CELL LINEAGE; CELL PROLIFERATION; DIMERIZATION; ERYTHROID CELLS; FEMALE; GENETIC VECTORS; GRANULOCYTES; JANUS KINASE 2; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TACROLIMUS; THROMBOPOIETIN;

EID: 4444356095     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.05.014     Document Type: Article

References (42)

1. Spencer D.M. Wandless T.J. Schreiber S.L. Crabtree G.R. Controlling signal transduction with synthetic ligands Science 262 1993 1019-1024
2. Neff T. Blau C.A. Pharmacologically regulated cell therapy Blood 97 2001 2535-2540
3. Blau C.A. Peterson K.R. Drachman J.G. Spencer D.M. A proliferation switch for genetically modified cells Proc. Natl. Acad. Sci. USA 94 1997 3076-3081
4. Ito K. et al. Development of a novel selective amplifier gene for controllable expansion of transduced hematopoietic cells Blood 90 1997 3884-3892
5. Jin L. Asano H. Blau C.A. Stimulating cell proliferation through the pharmacologic activation of c-kit Blood 91 1998 890-897
6. Jin L. et al. Targeted expansion of genetically modified bone marrow cells Proc. Natl. Acad. Sci. USA 95 1998 8093-8097
7. Xu R. et al. A selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells J. Gene Med. 1999
8. Zeng H. Masuko M. Jin L. Neff T. Otto K.G. Blau C.A. Receptor specificity in the self-renewal and differentiation of primary multipotential hemopoietic cells Blood 98 2001 328-334
9. Richard R.E. Wood B. Zeng H. Papayannopoulou T. Blau C.A. Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization Blood 95 2000 430-436
10. Richard R.E. Blau C.A. Selective expansion of genetically modified cord blood cells Stem Cells 21 2003 71-78
11. Jin L. et al. In vivo selection using a cell growth switch Nat. Genet. 26 2000 64-66
12. Richard R.E. Weinreich M. Chang K.-H. Ieremia J. Stevenson M.M. Blau C.A. Modulating erythrocyte mixed chimerism in a mouse model of pyruvate kinase deficiency Blood 2004 (in press)
13. Neff T. et al. Pharmacologically regulated in vivo selection in a large animal Blood 100 2002 2026-2031
14. Witthuhn B.A. et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin Cell 74 1993 227-236
15. Drachman J.G. Griffin J.D. Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl J. Biol. Chem. 270 1995 4979-4982
16. Miyakawa Y. et al. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets Blood 86 1995 23-27
17. Tortolani P.J. et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2 Blood 85 1995 3444-3451
18. Sattler M. et al. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases Exp. Hematol. 23 1995 1040-1048
19. Silvennoinen O. Witthuhn B.A. Quelle F.W. Cleveland J.L. Yi T. Ihle J.N. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction Proc. Natl. Acad. Sci. USA 90 1993 8429-8433
20. Quelle F.W. et al. JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region Mol. Cell Biol. 14 1994 4335-4341
21. Sato S. et al. IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases J. Exp. Med. 180 1994 2101-2111
22. Campbell G.S. Argetsinger L.S. Ihle J.N. Kelly P.A. Rillema J.A. Carter-Su C. Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants Proc. Natl. Acad. Sci. USA 91 1994 5232-5236
23. Argetsinger L.S. et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase Cell 74 1993 237-244
24. Parganas E. et al. Jak2 is essential for signaling through a variety of cytokine receptors Cell 93 1998 385-395
25. Neubauer H. Cumano A. Muller M. Wu H. Huffstadt U. Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis Cell 93 1998 397-409
26. Otto K.G. et al. Membrane localization is not required for Mpl function in normal hematopoietic cells Blood 98 2001 2077-2083
27. Zhao S. et al. JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells EMBO J. 21 2002 2159-2167
28. Matz M.V. et al. Fluorescent proteins from nonbioluminescent Anthozoa species Nat. Biotechnol. 17 1999 969-973
29. Abboud M. Laver J. Blau C.A. Granulocytosis causing sickle-cell crisis Lancet 351 1998 959
30. Adler B.K. Salzman D.E. Carabasi M.H. Vaughan W.P. Reddy V.V. Prchal J.T. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration Blood 97 2001 3313-3314
31. + thalassemia Blood 97 2001 3998-3999
32. Gough P.J. Raines E.W. Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector Blood 101 2003 485-491
33. Moreau-Gaudry F. et al. High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors Blood 98 2001 2664-2672
34. Schwaller J. et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes EMBO J. 18 1998 5321-5333
35. Schwaller J. et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2 Mol. Cell 6 2000 693-704
36. Singer A. New perspectives on a developmental dilemma: the kinetic signaling model and the importance of signal duration for the CD4/CD8 lineage decision Curr. Opin. Immunol. 14 2002 207-215
37. Singer A.L. Koretzky G.A. Control of T cell function by positive and negative regulators Science 296 2002 1639-1640
38. Kamizono S. et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2 J. Biol. Chem. 276 2001 12530-12538
39. Frantsve J. Schwaller J. Sternberg D.W. Kutok J. Gilliland D.G. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation Mol. Cell. Biol. 21 2001 3547-3557
40. Rouyez M.C. Boucheron C. Gisselbrecht S. Dusanter-Fourt I. Porteu F. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway Mol. Cell. Biol. 17 1997 4991-5000
41. Rojnuckarin P. Drachman J.G. Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis Blood 94 1999 1273-1282
42. Thomis D.C. et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease Blood 97 2001 1249-1257